Clinical Trial Success for ImmunityBio Overshadowed by Regulatory Scrutiny

ImmunityBio's ANKTIVA trial meets key statistical goal, but FDA warning letter triggers an 8.6% stock drop. The firm sees surging sales while facing legal probes.

ImmunityBio announced on Thursday that its pivotal QUILT-2.005 registration trial has reached a key statistical milestone. The study, which is evaluating the company's drug ANKTIVA in combination with BCG for BCG-naive bladder cancer patients, is now sufficiently powered to meet its primary endpoints. This clinical progress, however, arrives alongside significant regulatory challenges for the biopharmaceutical firm.

Commercial Momentum and Legal Headwinds

Despite the regulatory pressure, ImmunityBio's commercial performance shows notable strength. The company reported global ANKTIVA sales of approximately $113 million for 2025. Market analysts project 2026 revenue to reach around $217.6 million, a forecast supported by the year-over-year sales surge of 700% reported in February 2026 and the therapy's expansion into 33 countries. Most recently, on March 20, the company secured its first Asian market approval in Macau.

Concurrently, the firm faces investigations from law firms, including Pomerantz LLP and the Rosen Law Firm, concerning potential violations of securities laws. These probes focus on whether the company or its executives made misleading statements regarding ANKTIVA's clinical capabilities. The financial impact of these legal matters and their potential to disrupt commercial momentum will become clearer with the release of upcoming quarterly financial results.

FDA Warning Letter Triggers Stock Decline

The positive clinical update was immediately countered by substantial regulatory pressure. On March 24, the U.S. Food and Drug Administration (FDA) issued a warning letter criticizing ImmunityBio for misleading promotional claims. The agency specifically cited a television advertisement and an executive podcast that, in its view, suggested ANKTIVA could "cure" cancer or prevent its recurrence—claims not supported by the approved product labeling or clinical data. ImmunityBio must cease using the cited materials and provide a written response to the FDA within 15 working days.

The market reacted negatively to this development. On Thursday, the company's shares fell by 8.6%, dipping to $7.22 at their lowest point during the trading session.

Trial Data and Regulatory Pathway

The latest clinical assessment comes from an independent data monitoring committee (IDMC), which completed a planned interim analysis. Out of the 366 patients fully enrolled in the QUILT-2.005 trial, data from approximately 183 participants is currently evaluable for the primary efficacy endpoint. This endpoint measures the response rate comparison between ANKTIVA plus BCG and BCG alone. The company stated that no further patient recruitment is necessary. ImmunityBio plans to submit a supplemental Biologics License Application (sBLA) for this indication by the end of 2026.